55-27-6

Basic information

• Product Name: DL-NORADRENALINE HYDROCHLORIDE
• Synonyms: (+/-)-NORADRENALIN HYDROCHLORIDE;[+-]-NORADRENALIN HYDROCHLORIDE;(+/-)-NOREPINEPHRINE HYDROCHLORIDE;[+-]-NOREPINEPHRINE HYDROCHLORIDE;2-AMINO-1-(3,4-DIHYDROXYPHENYL)ETHANOL HYDROCHLORIDE;(+/-)-3,4-DIHYDROXYPHENYLETHANOLAMINE HYDROCHLORIDE;3,4-DIHYDROXYPHENYLETHANOLAMINE HYDROCHLORIDE;(+/-)-1-(3,4-DIHYDROXYPHENYL)-2-AMINOETHANOL HYDROCHLORIDE
• CAS NO: 55-27-6
• Molecular Formula: C₈H₁₂NO₃*Cl
• Molecular Weight: 205.64
• EINECS: 200-229-8
• Product Categories: Standards - 13C & 2H for GC-Mass Spectrometry;Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 55-27-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 140-144 °C (dec.)
• Boiling Point: 442.6°Cat760mmHg
• Flash Point: 221.5°C
• Appearance: off-white to tan/crystalline
• Density: 1.397g/cm³
• Vapor Pressure: 1.3E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: water: soluble50mg/mL, clear to slightly hazy, faintly yellow to
• BRN: 3707003
• CAS DataBase Reference: DL-NORADRENALINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DL-NORADRENALINE HYDROCHLORIDE(55-27-6)
• EPA Substance Registry System: DL-NORADRENALINE HYDROCHLORIDE(55-27-6)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 36/37/39-45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• RTECS: DN6650000
• F: 10
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 55-27-6(Hazardous Substances Data)

Usage

Description

DL-NORADRENALINE HYDROCHLORIDE, also known as DL-Norepinephrine hydrochloride, is an adrenergic drug with chemical properties of a white to off-white solid. It is a compound that plays a significant role in the study and treatment of various physiological and medical conditions.

Uses

Used in Pharmaceutical and Medical Research:
DL-NORADRENALINE HYDROCHLORIDE is used as a research compound for investigating the effects of adrenergic drugs on the lantern of larval fly. This application helps in understanding the role of adrenergic drugs in biological systems and their potential impact on various organisms.
Used in Cardiology Studies:
In the field of cardiology, DL-NORADRENALINE HYDROCHLORIDE is used as a pharmacological tool to evaluate the ability of α-adrenergic stimulation in the presence of elevated calcium levels to induce delayed after depolarizations and triggered activity in Purkinje fibers isolated from cat hearts. This application aids in understanding the mechanisms of cardiac arrhythmias and the potential therapeutic interventions.
Used in Material Science and Nanotechnology:
DL-NORADRENALINE HYDROCHLORIDE is used as a reducing and surface functionalization agent in the simultaneous reduction and surface functionalization of graphene oxide through a one-step poly(norepinephrine) functionalization process. This application is crucial in the development of advanced materials with tailored properties for various applications, including energy storage, sensors, and electronics.

Safety Profile

Poison by intraperitoneal andsubcutaneous routes. Experimental reproductive effects.When heated to decomposition it emits toxic fumes ofNOx and HCl.

InChI:InChI=1/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/p+1/t8-/m0/s1

Upstream product

• 1207201-66-8 tert-butyl 2-(3,4-dihydroxyphenyl)-2-hydroxyethylcarbamate 
• 5090-29-9 1-(3,4-dihydroxyphenyl)-1-oxo-2-amino-ethan-hydrochlorid 

Downstream Products

• 95483-81-1 {4-[2-(3,4-Dihydroxy-phenyl)-2-hydroxy-ethylamino]-pentyl}-carbamic acid benzyl ester; hydrochloride 
• 88719-61-3 {5-[2-(3,4-Dihydroxy-phenyl)-2-hydroxy-ethylamino]-hexyl}-carbamic acid benzyl ester; hydrochloride 
• 18933-25-0 STO 41424 
• 88719-63-5 N-<5-<<(cyclohexylamino)carbonyl>oxy>-2-pentyl>norepinephrine 
• 88719-65-7 {4-[2-(3,4-Dihydroxy-phenyl)-2-hydroxy-ethylamino]-pentyl}-carbamic acid cyclohexyl ester; hydrochloride 
• 95483-80-0 {3-[2-(3,4-Dihydroxy-phenyl)-2-hydroxy-ethylamino]-butyl}-carbamic acid benzyl ester; hydrochloride 
• 88733-16-8 1-{5-[2-(3,4-Dihydroxy-phenyl)-2-hydroxy-ethylamino]-hexyl}-3-p-tolyl-urea; hydrochloride 
• 95483-02-6 (4-Methyl-benzoyl)-carbamic acid 4-[2-(3,4-dihydroxy-phenyl)-2-hydroxy-ethylamino]-pentyl ester 
• 95483-85-5 {6-[2-(3,4-Dihydroxy-phenyl)-2-hydroxy-ethylamino]-heptyl}-carbamic acid benzyl ester; hydrochloride 
• 95484-08-5 C₂₉H₄₂N₆O₇*ClH 
• 24159-36-2 dopamine β-sulfonate 
• 88719-46-4 N-{3-[2-(3,4-Dihydroxy-phenyl)-2-hydroxy-ethylamino]-butyl}-4-methyl-benzamide; hydrochloride 
• 95483-99-1 N-{4-[2-(3,4-Dihydroxy-phenyl)-2-hydroxy-ethylamino]-pentyl}-2-methyl-benzamide; hydrochloride 
• 88719-47-5 N-{4-[2-(3,4-Dihydroxy-phenyl)-2-hydroxy-ethylamino]-pentyl}-4-methyl-benzamide; hydrochloride 

Relevant articles and documents

PROCESS FOR PREPARATION OF (DL) -NOREPINEPHRINE ACID ADDITION SALT, A KEY INTERMEDIATE OF (R) - (-) - NOREPINEPHRINE

The invention discloses a process for preparation of (dl)-norepinephrine salt by reacting 3,4-dihydroxy-a-haloacetophenone with hexamethylenetetramine to provide hexamine salt; followed by hydrolysis and hydrogenation. The invention also discloses a novel intermediate formed in the process and its synthesis.

On the interactions of catecholamines with N-methylnicotinamide cation: A UV spectral study

-